Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Elizabeth Miller

Physician Assistant, Surgical Portland, OR Physician Assistant

NPI 1306303466 CMS profile 10850786

7421 Sw Bridgeport Rd Ste 215, Portland, OR 97224

Open in the dashboard

General payments

$3,202

52 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Elizabeth Miller of Portland, OR is reported in the CMS Open Payments database as having received $3,202 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,495 14
2022 General $1,488 24
2021 General $219 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Miller
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Elizabeth Miller were reported at $0. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Elizabeth Miller Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $219 $111 $36–$285 $132
2022 $1,488 $126 $44–$350 $149
2023 $1,495 $137 $47–$355 $160
2024 $0 $146 $49–$384 $164
2025 $0 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Axonics Modulation Technologies, Inc. $1,284 11 payments
  2. Medtronic, Inc. $1,218 14 payments
  3. Smith+Nephew, Inc. $342 6 payments
  4. Janssen Pharmaceuticals, Inc $325 19 payments
  5. Pfizer Inc. $20 1 payment
  6. E.R. Squibb & Sons, L.L.C. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Travel and Lodging $1,831 12 payments
  2. Food and Beverage $1,371 40 payments
Products named General payments · program years 2021–2023
  1. Axonics $1,284 11 payments
  2. VENASEAL $1,218 14 payments
  3. XARELTO $325 19 payments
  4. K-15 PORK $184 2 payments
  5. LEGION $112 3 payments
  6. R3 ACETABULAR $112 2 payments
  7. LEGION Revision $46 1 payment
  8. REDAPT $39 1 payment
  9. JOURNEY II $28 1 payment
  10. ELIQUIS $20 1 payment
  11. Other $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

551

Median for Physician Assistant: 241

Drug cost

$184,747

Median for Physician Assistant: $4,110

Branded share of claims

60.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 135 $116,274
Myrbetriq Mirabegron Brand 52 $46,502
Estradiol Generic 137 $8,595
Premarin Estrogens, Conjugated Brand 21 $8,209
Trospium Chloride Er Trospium Chloride Brand 14 $2,598
Trospium Chloride Generic 21 $977
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 93 $715
Solifenacin Succinate Generic 18 $457
Cephalexin Generic 41 $337
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$68,536

Of which drugs: $25,416

Medicare patients

213

Average age 75

Services billed

5,870

213 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 54%
Depression 31%
Osteoporosis 24%
Diabetes 19%
Cancer 15%
Chronic kidney disease 13%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 35 5,200 $25,413

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record